Table 1.

TB risk associated to the different biological drugs used for rheumatic patients.

Mechanism of Action	Biologic	Rheumatologic indications	TB risk	TB screening mandatory
TNF Inhibitors	Infliximab Adalimumab Etanercept Golimumab Certolizumab Pegol	RA, PsA, SpA	High High Medium/High Medium/High Medium/High	Yes
IL-6R Inhibitors	Tocilizumab Sarilumab	RA	Medium	Yes
JAK Inhibitors	Tofacitinib Baricitinib Upadacitinib Filgotinib	RA, PsA, SpA RA RA, PsA, SpA RA	Medium	Yes
CTLA4-Ig	Abatacept	RA, PsA	Low	Yes
IL-12/23 Inhibitor	Ustekinumab	PsA	Low	Yes
IL-23 Inhibitors	Guselkumab Risankizumab	PsA	Low	Yes
IL-17 Inhibitors	Secukinumab Ixekizumab	PsA, SpA	Low	Yes
CD20 Inhibitor	Rituximab	RA	Low	No
PDE4 Inhibitor	Apremilast	PsA	Low	No

*Risk based on mechanism of action and TB IR before the introduction of systematic TB screening.